2 terminated. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
| Phase 2 | 2 | Terminated 2 |
Follow RCC: new trials by email Literature Review of RCC trials Research Report on RCC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors CB-839, Talazoparib - Solid Tumor, Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Calithera Biosciences, Inc | 33 | 2019-05-20 | 2022-02-17 |
| Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) Ixazomib, Pegylated IFN-alpha 2b - Metastatic Renal Cell Carcinoma, RCC | Phase 1 / Phase 2 | Terminated | Fox Chase Cancer Center | 3 | 2015-08-14 | 2019-09-26 |
Carcinoma, Renal Cell (2) · Colorectal Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Adenocarcinoma (2) · Carcinoma (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Kidney Neoplasms (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2) · Urologic Neoplasms (2)
CB-839 (1) · ixazomib (1) · talazoparib (1)
Calithera Biosciences, Inc (1) · Fox Chase Cancer Center (1)
United States (2)